
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.
Ryan Kohlhepp of Bicara told Bank of America analyst Tazeen Ahmad that the Boston-based biotechnology company is focused on large-molecule bifunctional antibodies for solid tumor oncology. Its lead program, ficerafusp alfa, targets EGFR and TGF-beta, with the goal of using EGFR-mediated tumor targeting to deliver TGF-beta inhibition more effectively to tumors.